Shares of AstraZeneca PLC (LON:AZN - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of £114.30 ($147.30) and traded as high as £120.18 ($154.87). AstraZeneca shares last traded at £119.30 ($153.73), with a volume of 3,374,392 shares trading hands.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. Shore Capital restated a "buy" rating on shares of AstraZeneca in a research report on Friday. Berenberg Bank reaffirmed a "buy" rating and set a GBX 140 ($1.80) price target on shares of AstraZeneca in a research note on Monday, January 27th. Finally, JPMorgan Chase & Co. reiterated an "overweight" rating on shares of AstraZeneca in a report on Wednesday, February 19th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of GBX 7,542.80 ($97.20).
Check Out Our Latest Stock Report on AZN
AstraZeneca Stock Performance
The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The firm has a 50 day moving average price of £112.76 and a 200 day moving average price of £114.26. The stock has a market cap of £232.27 billion, a PE ratio of 33.09, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.
About AstraZeneca
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
